The article mentions that analysts have provided bullish ratings for Cullinan Oncology in the last quarter. The average 12-month price target is $49.25, which is a 1.5% decrease from the previous average price target of $50.00. This indicates that analysts are positive about the stock's performance, which could lead to an increase in its stock price in the short term.